Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more
Market Cap & Net Worth: Biohit Oyj B (BIOBV)
Biohit Oyj B (HE:BIOBV) has a market capitalization of $30.74 Million (€29.94 Million) as of March 18, 2026. Listed on the HE stock exchange, this Finland-based company holds position #25518 globally and #95 in its home market, demonstrating a 2.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biohit Oyj B's stock price €2.45 by its total outstanding shares 12222093 (12.22 Million).
Biohit Oyj B Market Cap History: 2015 to 2026
Biohit Oyj B's market capitalization history from 2015 to 2026. Data shows change from $70.38 Million to $30.74 Million (-7.97% CAGR).
Biohit Oyj B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biohit Oyj B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.95x
Biohit Oyj B's market cap is 2.95 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
17.15x
Biohit Oyj B's market cap is 17.15 times its annual earnings
1.95x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $75.90 Million | $8.20 Million | -$3.29 Million | 9.26x | N/A |
| 2017 | $47.30 Million | $8.98 Million | $6.14 Million | 5.27x | 7.70x |
| 2018 | $37.14 Million | $9.93 Million | -$2.14 Million | 3.74x | N/A |
| 2019 | $42.15 Million | $10.05 Million | -$1.42 Million | 4.19x | N/A |
| 2020 | $31.11 Million | $7.12 Million | -$3.31 Million | 4.37x | N/A |
| 2021 | $23.02 Million | $9.36 Million | -$1.50 Million | 2.46x | N/A |
| 2022 | $19.70 Million | $10.95 Million | $601.00K | 1.80x | 32.77x |
| 2023 | $23.65 Million | $13.08 Million | $1.85 Million | 1.81x | 12.78x |
| 2024 | $28.73 Million | $14.30 Million | $2.60 Million | 2.01x | 11.05x |
| 2025 | $46.29 Million | $15.70 Million | $2.70 Million | 2.95x | 17.15x |
Competitor Companies of BIOBV by Market Capitalization
Companies near Biohit Oyj B in the global market cap rankings as of March 18, 2026.
Key companies related to Biohit Oyj B by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Biohit Oyj B Historical Marketcap From 2015 to 2026
Between 2015 and today, Biohit Oyj B's market cap moved from $70.38 Million to $ 30.74 Million, with a yearly change of -7.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €30.74 Million | -33.60% |
| 2025 | €46.29 Million | +61.14% |
| 2024 | €28.73 Million | +21.49% |
| 2023 | €23.65 Million | +20.06% |
| 2022 | €19.70 Million | -14.44% |
| 2021 | €23.02 Million | -26.01% |
| 2020 | €31.11 Million | -26.19% |
| 2019 | €42.15 Million | +13.51% |
| 2018 | €37.14 Million | -21.49% |
| 2017 | €47.30 Million | -37.69% |
| 2016 | €75.90 Million | +7.84% |
| 2015 | €70.38 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Biohit Oyj B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.74 Million USD |
| MoneyControl | $30.74 Million USD |
| MarketWatch | $30.74 Million USD |
| marketcap.company | $30.74 Million USD |
| Reuters | $30.74 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.